Other
Exercised (in shares)
Xylem Exercised (in shares) increased by 262.6% to $45.33 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 31.0%, from $65.65 to $45.33. Over 4 years (FY 2021 to FY 2025), Exercised (in shares) shows an upward trend with a 8.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalLower is better
VolatilityModerate
First reportedQ1 2015
Last reportedQ1 2026Apr 28, 2026
How to read this metric
Higher numbers indicate greater dilution of existing shareholders through compensation plans.
Detailed definition
The total volume of shares issued or transferred to satisfy obligations under various share-based payment arrangements....
Peer comparison
Standard disclosure in equity and cash flow statements.
Metric ID:
other_share_based_compensation_arrangements_by_share_bas_83b57cHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.38 | -$3.57 | $0.00 | $42.35 | $5.72 | $9.45 | $2.55 | $48.39 | -$20.13 | $1.12 | $3.02 | $51.72 | $9.50 | $0.31 | $0.03 | $65.65 | -$2.00 | $1.09 | $12.50 | $45.33 |
| QoQ Change | — | -358.7% | +100.0% | — | -86.5% | +65.2% | -73.0% | >999% | -141.6% | +105.6% | +169.6% | >999% | -81.6% | -96.7% | -90.3% | >999% | -103.0% | +154.5% | >999% | +262.6% |
| YoY Change | — | — | — | — | +314.5% | +364.7% | — | +14.3% | -451.9% | -88.1% | +18.4% | +6.9% | +147.2% | -72.3% | -99.0% | +26.9% | -121.1% | +251.6% | >999% | -31.0% |
Range-$20.13 – $65.65
CAGR+108.6%
Avg YoY Growth>999%
Median YoY Growth+14.3%
Current Streak3 quarters growth
Exercised (in shares) at Other Companies
Frequently Asked Questions
- What is Xylem's exercised (in shares)?
- Xylem (XYL) reported exercised (in shares) of $45.33 in Q1 2026.
- How has Xylem's exercised (in shares) changed year-over-year?
- Xylem's exercised (in shares) decreased by 31.0% year-over-year, from $65.65 to $45.33.
- What is the long-term trend for Xylem's exercised (in shares)?
- Over 4 years (2021 to 2025), Xylem's exercised (in shares) has grown at a 8.9% compound annual growth rate (CAGR), from $54.82 to $77.24.
- What does exercised (in shares) mean?
- The total number of shares distributed to satisfy all equity compensation awards.